Drug Profile
Nemvaleukin alfa - Alkermes plc
Alternative Names: ALKS-4230; Nemvaleukin; RDB 1450; RDB-1419Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Alkermes plc
- Developer Alkermes plc; Merck Sharp & Dohme; Mural Oncology
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase II Malignant melanoma; Solid tumours; Squamous cell cancer
- Preclinical Small cell lung cancer
Most Recent Events
- 26 Mar 2024 Pharmacodynamics and adverse events data from the phase I/II ARTISTRY-3 trial in Solid tumours released by Mural Oncology
- 02 Aug 2023 Mural Oncology completes the phase-I/II ARTISTRY-1 trial in Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in Australia, Belgium, Canada, South Korea, Poland, Spain and USA (IV) (NCT02799095)
- 14 Apr 2023 Pharmacodynamic data from a preclinical study in Malignant melanoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)